PMV Pharmaceuticals Company Profile - aVenture Research
PMV Pharmaceuticals
PMV Pharmaceuticals develops small-molecule precision oncology therapies via selective p53 Y220C reactivation, with rezatapopt in trials for advanced solid tumors.
PMV Pharmaceuticals is a precision oncology platform company pursuing tumor-agnostic therapies that target specific genetic alterations rather than a single cancer or tissue type. The platform leverages more than four decades of research experience and insights into the p53 protein.
Its lead candidate, rezatapopt, is an oral small molecule for locally advanced or metastatic solid tumors carrying a p53 Y220C mutation, and the US FDA has granted it Fast Track designation. Rezatapopt remains an investigational product that no regulatory authority, including the FDA, has approved, and it is being studied in clinical trials both alone and in combination with pembrolizumab.